Marijuana Stocks: Why Tilray Inc. (NASDAQ:TLRY) Remains a Top Buy

The price chart of Tilray (NASDAQ:TLRY) stock shows that a manic buying rush, which pushed this top marijuana stock to $300 a share past year, has ended.  One bit of evidence of this maturity came last week when the company reported its first full quarter after Canada legalized recreational consumption of cannabis in October last year. Tilray, a British Columbia-based medical…

Read More

Aurora Cannabis (TSX:ACB) vs. Cronos Group (TSX:CRON): Which Market Beater Has More Long-Term Upside?

Are you interested in pot stocks? If you are, you’re not alone. Pot stocks are very popular, and for good reasons. While the TSX has returned about 13% year to date, Horizons Marijuana Life Sciences ETF (TSX:HMMJ) is up 62% year to date. So, the marijuana sector in general is outperforming the whole market. But there are two pot stocks…

Read More

3 Marijuana Stocks to Consider Buying in April

Heading into April, the marijuana industry is once again on the rise. After a terrible end to 2018, Canada’s pot stocks are going up, with many of them approaching last year’s highs. Following encouraging Q3 results from Canopy, there’s a renewed sense of optimism about the marijuana industry. This time, however, it’s not necessarily Canopy that’s stealing the spotlight. If you’re…

Read More

Vitalibis, Inc. (OTCQB: VCBD) Surges 35% After Announcing Business Alliance Agreement with Aromatics International

Vitalibis, Inc.

Vitalibis, Inc. (OTCQB: VCBD) is engaged in the development and commercialization of hemp-based CBD products. Shares surged 34.55% on Tuesday, January 22, 2019. Over the past month, Vitalibis has seen an average daily volume of 5,510 shares. However, on Tuesday, 31,384 shares traded hands, equating to $46,450 in dollar volume. Shares surged on Tuesday after Vitalibis announced it has entered…

Read More

New report: Are prescriptions contributing to the opioid crisis? Canadians are taking increased doses despite national guidelines

Reformulary Group

TORONTO, Jan. 22, 2019 (GLOBE NEWSWIRE) — Reformulary Group, a Canadian healthcare technology company, today released a report on opioid prescribing in Canada. The report analyzes the data of over six million prescription Canadians that submitted a drug claim from 2013 to 2017 to address the impact of prescription opioids on the health and safety of all Canadians. The report,…

Read More